+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease



Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease



Neuropsychobiology 45(3): 156-160



Earlier studies of cognitive event-related brain potentials (ERPs) reporting diminished amplitudes and delayed latencies of the P300 potential in dementia of the Alzheimer type (DAT), together with independent findings of the P300- and performance-enhancing properties of nicotine in normal adults, stimulated this study to explore the single-dose effects of nicotine on auditory and visual P300s in DAT. Thirteen patients, 6 currently receiving treatment with the cholinesterase inhibitor tacrine (tetrahydroaminoacridine; THA) and the remaining being medication free, were administered 2 mg of nicotine polacrilex under double-blind, randomized, placebo-controlled conditions. Prior to nicotine administration, THA-treated patients exhibited shorter auditory P300 latencies than non-treated patients. Acutely administered nicotine failed to alter auditory P300, but increased the amplitudes of visual P300s in both DAT patient groups. Neither THA treatment nor single-dose nicotine altered behavioural performance in the visual and auditory task paradigms. The results are discussed in relation to nicotinic cholinergic, attentional and cognitive processes in DAT.

(PDF emailed within 0-6 h: $19.90)

Accession: 010544232

Download citation: RISBibTeXText

PMID: 11979067

DOI: 54957


Related references

Effects of Acute Nicotine Administration on Cognitive Event-Related Potentials in Tacrine-Treated and Non-Treated Patients with Alzheimer’s Disease. Neuropsychobiology 45(3): 156-160, 2002

Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study. Pharmacology, Biochemistry, and Behavior 72(1-2): 457-464, 2002

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proceedings of the National Academy of Sciences of the United States of America 89(23): 11466-11470, 1992

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proceedings of the National Academy of Sciences of the United States of America 89(23): 11471-5, 1992

Event-related potentials and cognitive functions in epileptic treated patients. Clinical Eeg 21(2): 67-73, 1990

Tri-axial recording of event-related potentials during passive cognitive tasks in patients with Alzheimer's disease. International Journal of Neuroscience 92(1-2): 29-45, 1998

Tri-axial recording of event-related potentials during passive cognitive tasks in patients with alzheimer's disease. International Journal of Neuroscience 92(1-2): 29-45, 1997

Event-related potentials in moderate cognitive impairment in patients with chronic cerebral ischemia treated with cytoflavin. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(8): 42-45, 2013

Should patients with Alzheimer's disease be treated with tacrine?. Tidsskrift for den Norske Laegeforening 116(23): 2791-2794, 1996

Clinical applications of cognitive event-related potentials in Alzheimer's disease. Physical Medicine and Rehabilitation Clinics of North America 15(1): 205-233, 2004

The role of event-related potentials in cognitive decline in Alzheimer's disease. Clinical Neurophysiology 121(2): 194-199, 2010

Cognitive event-related potentials: useful clinical information in Alzheimer's disease. Current Alzheimer Research 1(1): 63-69, 2005

Methodologic aspects of a population pharmacodynamic model for cognitive effects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proceedings of the National Academy of Sciences of the United States of America 89(23): 11466-11470, 1992

Event-related potentials for the diagnosis of mild cognitive impairment and Alzheimer's disease. Expert Opinion on Medical Diagnostics 6(1): 15-26, 2012

Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 10(3): 181-185, 1999